Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in Pulm Pharmacol Ther

Retrieve available abstracts of 11 articles:
HTML format

Single Articles

    August 2022
  1. CHEN H, Kunder R, Zou Y, Staton T, et al
    Effects of inhaled JAK inhibitor GDC-4379 on exhaled nitric oxide and peripheral biomarkers of inflammation.
    Pulm Pharmacol Ther. 2022;75:102133.
    PubMed     Abstract available

    July 2022
  2. TSUBOKAWA D, Satoh M
    Strongyloides venezuelensis-derived venestatin ameliorates asthma pathogenesis by suppressing receptor for advanced glycation end-products-mediated signaling.
    Pulm Pharmacol Ther. 2022 Jul 18:102148. doi: 10.1016/j.pupt.2022.102148.
    PubMed     Abstract available

    June 2022
  3. NAGASE H, Tamaoki J, Suzuki T, Nezu Y, et al
    Reduction in asthma exacerbation rate after mepolizumab treatment initiation in patients with severe asthma: A real-world database study in Japan.
    Pulm Pharmacol Ther. 2022 Jun 14:102130. doi: 10.1016/j.pupt.2022.102130.
    PubMed     Abstract available

    April 2022
  4. BUHL R, Nikolaev I, Tillmann HC, Vaidya S, et al
    Corrigendum to "Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/indacaterol/glycopyrronium in patients with asthma" [Pulm. Pharmacol. Therapeut. 70 (2021)
    Pulm Pharmacol Ther. 2022 Apr 11:102126. doi: 10.1016/j.pupt.2022.102126.

    March 2022
  5. CALZETTA L, Pistocchini E, Cito G, Ritondo BL, et al
    Inflammatory and contractile profile in LPS-challenged equine isolated bronchi: Evidence for IL-6 as a potential target against AHR in equine asthma.
    Pulm Pharmacol Ther. 2022 Mar 26:102125. doi: 10.1016/j.pupt.2022.102125.
    PubMed     Abstract available

    December 2021
  6. ZORAMPARI C, Prakash A, Rehan HS, Gupta LK, et al
    Serum dipeptidyl peptidase-4 and eosinophil cationic protein levels in patients of bronchial asthma.
    Pulm Pharmacol Ther. 2021 Dec 31:102109. doi: 10.1016/j.pupt.2021.102109.

  7. ZHU R, Owen R, Wilkins J, Schoemaker R, et al
    Pharmacokinetics and exposure-efficacy relationships of omalizumab in patients with nasal polyps.
    Pulm Pharmacol Ther. 2021;71:102080.
    PubMed     Abstract available

  8. ROSSI V, Salimaki J, Sandler C, Airaksinen M, et al
    Effectiveness of inhalation technique assessment service for patients with Respimat(R) inhaler.
    Pulm Pharmacol Ther. 2021;71:102077.
    PubMed     Abstract available

    October 2021
  9. SUTTON SS, Magagnoli J, Cummings TH, Hardin JW, et al
    Leukotriene Inhibition and the Risk of Lung Cancer among U.S. Veterans with Asthma.
    Pulm Pharmacol Ther. 2021 Oct 15:102084. doi: 10.1016/j.pupt.2021.102084.
    PubMed     Abstract available

  10. ALIDA B, Stefania P, Noemi CM, Maria I, et al
    Management of severe asthma during the first lockdown phase of SARS-CoV-2 pandemic: tips for facing the second wave.
    Pulm Pharmacol Ther. 2021 Oct 7:102083. doi: 10.1016/j.pupt.2021.102083.
    PubMed     Abstract available

  11. VAIDYA S, Ziegler D, Tanase AM, Malmqvist U, et al
    Pharmacokinetics of mometasone furoate delivered via two dry powder inhalers.
    Pulm Pharmacol Ther. 2021;70:102019.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Asthma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.